Improved RCC I/II-data

• 09:13

Immunicum AB (publ) today announced continued improvement in survival data from the follow-up phase of a clinical phase I/II trial in patients with metastatic renal cell cancer. Seven of eleven evaluable patients are still alive.

Read the press release here: Press release 150804 – RCC-update